
    
      A study of PEGylated recombinant human hyaluronidase (PEGPH20) administered on a twice weekly
      schedule for 28 days followed by a weekly dosing schedule in patients with advanced solid
      tumors who have either failed to respond to standard therapy or for whom no standard therapy
      exists.
    
  